Orgenesis Stock News

Millennium Management LLC lifted its stake in shares of Orgenesis Inc. (NASDAQ:ORGS) by 954.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 131,790 shares of the company’s stock after acquiring an additional 119,296 shares during the quarter. Millennium Management […]

Orgenesis Inc (NASDAQ: ORGS ) announced that its joint venture with Theracell Advanced Biotechnology S.A. in Greece has been designated a "Priority Investment of Strategic National Importance." The designation was awarded by Enterprise Greece, the official Greek national investment and trade promotion agency responsible for allocating the government funds. The joint venture will be inducted into Greece''s fast-track licensing and approval process. In addition, the joint venture will also receive Full story available on Benzinga.com

Orgenesis Inc (NASDAQ: ORGS) announced that its joint venture with Theracell Advanced Biotechnology S.A. in Greece has been designated a "Priority Investment of Strategic National Importance.

JV named a Priority Investment of Strategic National Importance by the government of Greece Granted fast-track licensing and approval status

Global biotech unlocking the potential of personalized therapies and closed processing systems helpful in manufacturing Maryland-based firm has a Cell and Gene Therapy (CGT) Biotech platform The platf

Orgenesis (NASDAQ:ORGS) Inc announced that its joint venture (JV) with Theracell Advanced Biotechnology SA in Greece has been designated a “Priority Investment of Strategic National Importance.” 

Orgenesis (NASDAQ:ORGS) Inc. said it entered into a collaboration agreement with Tel Aviv Sourasky Medical Center to establish a point-of-care (POCare) cell therapy center at the Ichilov Hospital, a

Orgenesis Inc. (ORGS) CEO Vered Caplan on Q3 2021 Results - Earnings Call Transcript

Orgenesis (NASDAQ:ORGS) Inc announced a more than five-fold increase in third-quarter revenue as it continues to roll out its Point of Care (POCare) platform.  The global biotech company, which is

GERMANTOWN, Md., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gen

Global biotech unlocking the potential of personalized therapies and closed processing systems helpful in manufacturing Maryland-based firm has a Cell and Gene Therapy (CGT) Biotech platform The platf

Orgenesis Inc announced a new collaboration with biotech firm Savicell Diagnostics Ltd to accelerate the development and manufacturing of its cell and gene therapy platform. The wide-ranging agreement

Goal to accelerate development, QC testing and manufacturing  of Orgenesis' cell and gene therapy platform

Orgenesis Inc said its 2Q 2021 revenues rose from $1.75 million to $10.5 million compared to the same period in 2020.  The international biotech company, which is focused on unlocking the full potent

GERMANTOWN, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gen